Last reviewed · How we verify
TPOXX
TPOXX inhibits orthopoxvirus protein synthesis by blocking viral RNA polymerase, preventing viral replication.
TPOXX inhibits orthopoxvirus protein synthesis by blocking viral RNA polymerase, preventing viral replication. Used for Smallpox (variola virus infection), Monkeypox (mpox), Vaccinia virus infection and other orthopoxvirus infections.
At a glance
| Generic name | TPOXX |
|---|---|
| Also known as | tecovirimat |
| Sponsor | SIGA Technologies |
| Drug class | Orthopoxvirus protein synthesis inhibitor |
| Target | Orthopoxvirus p37 protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
TPOXX (tecovirimat) is a small-molecule inhibitor that targets the viral protein p37, which is essential for orthopoxvirus maturation and egress from infected cells. By inhibiting p37, the drug prevents the formation of extracellular enveloped virus (EEV) particles, thereby blocking viral spread. This mechanism is effective against multiple orthopoxviruses including variola (smallpox), monkeypox, and vaccinia virus.
Approved indications
- Smallpox (variola virus infection)
- Monkeypox (mpox)
- Vaccinia virus infection and other orthopoxvirus infections
Common side effects
- Nausea
- Headache
- Abdominal pain
Key clinical trials
- Tecovirimat in Non-hospitalized Patients With Monkeypox (PHASE3)
- Study of Tecovirimat for Human Mpox Virus (PHASE3)
- Tecovirimat for Treatment of Monkeypox Virus (PHASE2)
- Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only
- Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS (PHASE2)
- Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease (PHASE3)
- European Trial Into Mpox Infection (PHASE4)
- Tecovirimat Intravenous Treatment for Orthopox Virus Exposure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TPOXX CI brief — competitive landscape report
- TPOXX updates RSS · CI watch RSS
- SIGA Technologies portfolio CI